文章核心观点 aTyr Pharma公司将在2025年美国胸科学会国际会议上展示其主要治疗候选药物efzofitimod的三张海报，该公司正在对efzofitimod进行多项临床试验研究 [1] 公司信息 - aTyr是临床阶段生物技术公司，利用进化智能将tRNA合成酶生物学转化为治疗纤维化和炎症的新疗法，其发现平台专注于解锁隐藏治疗干预点，主要治疗候选药物是efzofitimod [4] - 公司联系方式为投资者关系和公共事务高级总监Ashlee Dunston，邮箱adunston@atyrpharma.com [7] 药物信息 - efzofitimod是一流的生物免疫调节剂，正在进行治疗间质性肺病的临床开发，通过神经纤毛蛋白 - 2选择性调节活化的髓样细胞以解决炎症，且不抑制免疫并可能预防纤维化进展 [3] - 公司正在对efzofitimod进行两项研究，分别是针对肺结节病患者的全球3期EFZO - FIT™研究和针对系统性硬化症相关间质性肺病患者的2期EFZO - CONNECT™研究 [3] 海报信息 - 海报标题为“EFZO - FIT, Largest Placebo - Controlled Trial in Pulmonary Sarcoidosis – Trial Design and Patient Characteristics”，展示时间为2025年5月19日9:15AM – 4:15PM PT，地点在旧金山Moscone中心，所属会议环节为“Repair My Broken Lungs” [2] - 海报标题为“Real - World Treatment Patterns Among Pulmonary Sarcoidosis Patients with Parenchymal Involvement in the US”，展示时间为2025年5月18日9:15AM – 4:15PM PT，地点在旧金山Moscone中心，所属会议环节为“The Inflamed Lung: Sarcoidosis and Autoimmune Disease” [2] - 海报标题为“Incidence, Prevalence, and Mortality of Pulmonary Sarcoidosis with Parenchymal Involvement in the US”，展示时间为2025年5月20日9:15AM – 4:15PM PT，地点在旧金山Moscone中心，所属会议环节为“Current Insights into Risk, Diagnosis, and Treatment of Occupational and Environmental Lung Diseases” [2] 研究进展 - EFZO - FIT™研究的基线人口统计学和疾病特征已设盲，预计2025年第三季度公布该研究的 topline 数据 [1]

SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is scheduled to take place January 13 – 16, 2025, in San Francisco, CA. Details of the presentation appear below: C ...

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company’s Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine). “We are excited to welcome ...

公司动态 - 公司宣布将在2024年12月8日至11日于加拿大惠斯勒举行的Keystone纤维化专题研讨会上展示两张关于其tRNA合成酶候选药物ATYR0101的海报 [1] - 两张海报的展示环节均安排在2024年12月9日星期一晚上7点30分（PST），属于海报展示环节1 [3] - 海报标题一为“天冬氨酰-tRNA合成酶的一个新进化结构域与潜在转化生长因子β结合蛋白1相互作用以诱导肌成纤维细胞凋亡”，海报编号1046 [3] - 海报标题二为“基于天冬氨酰-tRNA合成酶的潜在疗法在肺和肾纤维化临床前模型中观察到抗纤维化活性”，海报编号1045 [3] - 海报在展示后将在公司网站上发布 [2] 公司业务与平台 - 公司是一家临床阶段生物技术公司，致力于从其专有的tRNA合成酶平台发现和开发首创药物 [1] - 公司利用进化智能将tRNA合成酶生物学转化为针对纤维化和炎症的新疗法 [4] - tRNA合成酶是古老的必需蛋白质，其在细胞外调控多种通路的新结构域已进化出来 [4] - 公司的发现平台专注于通过揭示由其源自全部20种tRNA合成酶的结构域库驱动的信号通路，来解锁隐藏的治疗干预点 [4] - 公司的主要治疗候选药物是efzofitimod，一种首创的生物免疫调节剂，正处于临床开发阶段，用于治疗间质性肺病 [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdic ...

财务数据关键指标变化：收入与利润 - 2024年第三季度归属于aTyr Pharma Inc.的净亏损为1726万美元[12] - 2024年第三季度基本和稀释后每股净亏损为0.23美元[12] - 2024年第三季度运营亏损为1814万美元[12] - 2024年第三季度其他收入总额净额为88万美元[12] 财务数据关键指标变化：成本与费用 - 2024年第三季度研发费用为1480万美元[7] - 2024年第三季度一般及行政费用为330万美元[7] - 2024年第三季度总运营费用为1814万美元[12] 其他财务数据 - 截至2024年9月30日，公司现金、现金等价物、受限现金和投资总额为6890万美元[7] - 2024年第三季度结束后，公司通过ATM发行筹集约1940万美元总收益[7] 业务线表现：研发进展 - 关键性3期EFZO-FIT™研究已完成268名患者入组，超过目标[5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction ...

Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second quarter 2024 with $81.4 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO – Augu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37378 | --- | --- | |------------------------------------------------------------------------------------------------------------------- ...